ClinicalTrials.gg
RecruitingNCT05938712HALLMARKUpdated May 1, 2026

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

A Phase 2 interventional study of Dapagliflozin 10 MG and Semaglutide, 1.0 mg/mL in Kidney Transplant Recipients, sponsored by University Health Network, Toronto. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by University Health Network, Toronto · Phase 2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 — 15 open to participants now, 19 under way, 5 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
160th of 180
20 · median 82
Started
2023
with 5 others
Phase 2
14 of 180
2 open now
Primary completion
2027-10
later than 12 of 18 live
Registered
160th of 180
by date

Among the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, this one is the 160th largest by planned enrollment, is one of 6 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 12 of the 18 other live ones, and was the 160th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

15 of the 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 180 studies testing dapagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

Read the detailed description

Kidney transplantation improves survival and quality of life for patients with kidney failure. However, treatment options to protect the heart and the kidney in transplant recipients are lacking. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) are novel anti-diabetic drugs which not only lower blood sugar, but also lower blood pressure in the kidney's individual filtering units and protect kidney function in the long term. It is unclear if the protective mechanisms of these drugs also occur in people with a kidney transplant. Several smaller studies have shown that SGLT2 inhibitors or GLP-1RA used alone are safe in people with kidney transplants. No studies have yet to look at the combined use of SGLT2 inhibitors and GLP-1RA in kidney transplant recipients (KTR).

The purpose of the HALLMARK study is to determine the mechanisms and safety of the combination use of semaglutide, a GLP-1RA, and dapagliflozin, a SGLT2 inhibitor. To investigate this, 20 kidney transplant recipients with and without diabetes will be treated with both semaglutide or dapagliflozin for 12 weeks followed by a combination of semaglutide and dapagliflozin for 12 weeks. The study will measure salt and water removal as well as the effect on blood pressure, kidney function, heart function, liver stiffness as well as the safety of these agents.

03

Conditions studied

  • Kidney Transplant Recipients

Keywords

  • Type 2 diabetes
  • SGLT2 inhibition
  • GLP-1 receptor agonist
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written .
  • Patients aged ≥18 years with KTR
  • >3 months post kidney transplantation
  • Estimated [eGFR] ≥20 ml/min/1.73m2
  • BP \<160/100 and >90/60 at screening
  • Body-mass index [] between 18.5-40kg/m2
  • In patients with T2D or PTDM, \<12.0%;

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes.
  • History of multi-organ transplant
  • Acute coronary syndrome, or stroke within 30 days prior to screening
  • Impending need for kidney or rapid decline in within 30 days prior to screening
  • Actively treated BK, CMV or EBV infection
  • Recurrent pyelonephritis or need for indwelling or self-catheterization
  • Prior amputation or ischemic rest pain
  • Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial.
  • History of pancreatitis
  • Personal or family history or medullary thyroid cancer or MEN2B
  • History of unstable diabetic retinopathy within 1 year prior to screening
  • Use of SGLT2i or GLP-1RA within 30 days prior to screening.
  • Current and frequent episodes of hypoglycemia
  • Current history of DKA requiring medical intervention or hospitalization
  • With current risk of volume depletion, hypotension and/or electrolyte imbalance
  • With known or suspected to semaglutide or related products
  • Patient not able to understand and comply with study requirements, based on Investigator's judgment.
  • Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcome (e.g. patients, active , patients who might be at higher risk of developing genital or mycotic infections, patients with chronic viral infections, uncontrolled hypertension, cardiorenal and/or hepatorenal syndrome etc.).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Semaglutide

    Semaglutide Subcutaneous 0.25mg once weekly for 4 weeks, then 0.5mg once weekly for 4 weeks, then 1mg once weekly for 4 weeks.

    Drug: Dapagliflozin 10 MG · Drug: Semaglutide, 1.0 mg/mL

  • Experimental
    Dapagliflozin

    Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks

    Drug: Dapagliflozin 10 MG · Drug: Semaglutide, 1.0 mg/mL

Interventions

06

What researchers measure

Primary outcomes

  1. Proximal tubular natriuresis with combination therapy

    Measured by fractional excretion of sodium

    Time frame: From baseline to combination therapy end (24 weeks)

  2. Proximal tubular natriuresis with monotherapy

    Measured by fractional excretion of sodium

    Time frame: From baseline to monotherapy end (12 weeks)

Secondary outcomes

  1. Measured Glomerular Filtration Rate

    GFR, based on plasma iohexol clearance

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  2. Estimated Glomerular Filtration Rate

    GFR, based on serum creatinine

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  3. Urinary 8-hydroxydeoxyguanosine and 8-isoprostane concentration

    Using ELISA

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  4. Urinary albumin excretion

    From 24-hour urine collection

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  5. Arterial stiffness

    Measured using a Sphygmocor device

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  6. Liver stiffness

    Using transient elastography

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  7. Diastolic function

    Using 2D echocardiography

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  8. Change in percentage of glycated hemoglobin (HbA1c)

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  9. Change in concentration of urine glucose excretion

    Urinary analysis will be performed to quantify the amount of glucose excretion.

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  10. Change in body composition (percent body mass, body fat, and muscle mass)

    Bioimpedence measurements will be taken to study the effects of intervention on body composition.

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  11. Change in body weight

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  12. Safety: the incidence of acute kidney injury.

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  13. Safety: the incidence of hypotension

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  14. Safety: The incidence of hyperkalemia

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  15. Safety: The incidence of urinary and mycotic infections.

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  16. Safety: The number of ketoacidosis events.

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  17. Safety: The incidence of amputations.

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  18. Safety: The incidence of pancreatitis or biliary complications

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

  19. Safety: The number of allergic reaction events.

    Time frame: From baseline to monotherapy end (12 weeks) and combination therapy end (24 weeks) ]

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2027, 47 months after the start.

Of 99 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 47 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2023
First posted
Jul 10, 2023
StartActual
Oct 24, 2023
Primary completionEst.
Oct 1, 2027
CompletionEst.
Mar 1, 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05938712
Responsible party
Sunita Singh, MD, MSc, FRCPC (Clinician Scientist, University Health Network, Toronto) — Principal investigator
First posted
Jul 10, 2023
Start date
Oct 24, 2023
Primary completion
Oct 1, 2027 (estimated)
Completion
Mar 1, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Vesta Lai
Contact
vesta.lai@uhn.ca
416-340-4800 ext. 8508
Sunita Singh, MD MSc FRCPC
principal investigator · University Health Network, Toronto General Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dapagliflozin · Semaglutide

Start the discussion